Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1159 | Educational outreach Wiki | 0.71 |
| drug342 | Audit and Feedback Wiki | 0.71 |
| drug2505 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001988 | Bronchiolitis NIH | 0.71 |
| D001987 | Bronchiectasis NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011950 | Bronchiolitis HPO | 0.71 |
| HP:0002110 | Bronchiectasis HPO | 0.41 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used and is readily available. It has a low rate of side effects and few interactions with other drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect. We propose to use inhaled and nasal ciclesonide to stop viral replication in the nose and airways. We hope this will accelerate recovery from COVID-19 illness in individuals who are not admitted to hospital at time of diagnosis of COVID-19.
Description: Dyspnea improvement is defined as a 15%, or greater, decline in dyspnea intensity. To measure dyspnea intensity, we will use a validated patient reported outcome measure called the Promis dyspnea characteristics scale.
Measure: Improvement in dyspnea at day 7 Time: day 7Description: Hospitalization for SARS-CoV-2 related illness at day 14
Measure: Hospitalization at day 14 Time: day 14Description: Incidence and duration of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14
Measure: Oxygen Use Time: day 14Description: All cause mortality
Measure: Mortality Time: day 14 and 29Description: Ordinal Scale for Evaluating subject Clinical Status at day 7 and 14
Measure: Clinical status Time: day 7 and 14Description: Promis Anxiety 7a scale
Measure: Anxiety Time: day 7 and 14Description: Promis Sleep disturbance 4a scale
Measure: Sleep Disturbance Time: day 7 and 14Description: The "Three-minute step test" will be measured in men and women to determine the impact of SARS-CoV-2 on exercise capacity
Measure: Exercise capacity Time: day 7 and 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports